| Attribute |
Value |
| 52 Week Change |
-0.29555553 |
| Address1 |
Chemin des Mines, 9 |
| All Time High |
750.4 |
| All Time Low |
5.0 |
| Ask |
6.4 |
| Ask Size |
1 |
| Average Daily Volume10 Day |
2,110 |
| Average Daily Volume3 Month |
3,939 |
| Average Volume |
3,939 |
| Average Volume10Days |
2,110 |
| Beta |
1.994 |
| Bid |
6.06 |
| Bid Size |
2 |
| Book Value |
4.15081 |
| City |
Geneva |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Switzerland |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
5.71 |
| Current Ratio |
0.973 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
6.31 |
| Day Low |
5.68 |
| Debt To Equity |
3.112 |
| Display Name |
Addex Therapeutics |
| Earnings Call Timestamp End |
1,745,589,600 |
| Earnings Call Timestamp Start |
1,745,589,600 |
| Earnings Timestamp End |
1,756,702,800 |
| Earnings Timestamp Start |
1,756,702,800 |
| Ebitda |
-2,689,751 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-1.801 |
| Enterprise To Revenue |
44.246 |
| Enterprise Value |
4,844,707 |
| Eps Forward |
-0.05 |
| Eps Trailing Twelve Months |
-8.49 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
41 22 884 1556 |
| Fifty Day Average |
6.4554 |
| Fifty Day Average Change |
-0.74539995 |
| Fifty Day Average Change Percent |
-0.11546921 |
| Fifty Two Week Change Percent |
-29.555553 |
| Fifty Two Week High |
12.05 |
| Fifty Two Week High Change |
-6.34 |
| Fifty Two Week High Change Percent |
-0.5261411 |
| Fifty Two Week Low |
5.41 |
| Fifty Two Week Low Change |
0.3000002 |
| Fifty Two Week Low Change Percent |
0.055452902 |
| Fifty Two Week Range |
5.41 - 12.05 |
| Financial Currency |
CHF |
| First Trade Date Milliseconds |
1,581,517,800,000 |
| Float Shares |
808,873 |
| Forward Eps |
-0.05 |
| Forward P E |
-114.2 |
| Free Cashflow |
-1,524,704 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
3 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-442,218 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.0 |
| Held Percent Institutions |
0.00037999998 |
| Implied Shares Outstanding |
1,265,844 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,698,019,200 |
| Last Split Factor |
1:20 |
| Long Business Summary |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. |
| Long Name |
Addex Therapeutics Ltd |
| Market |
us_market |
| Market Cap |
7,227,969 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_2573627 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-7,081,464 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
8,071,371 |
| Open |
5.84 |
| Operating Cashflow |
-2,338,253 |
| Operating Margins |
-62.38812 |
| Payout Ratio |
0.0 |
| Phone |
41 22 884 1555 |
| Previous Close |
6.34 |
| Price Hint |
2 |
| Price To Book |
1.3756351 |
| Price To Sales Trailing12 Months |
66.01126 |
| Profit Margins |
0.0 |
| Quick Ratio |
0.791 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.63 |
| Regular Market Change Percent |
-9.93691 |
| Regular Market Day High |
6.31 |
| Regular Market Day Low |
5.68 |
| Regular Market Day Range |
5.68 - 6.31 |
| Regular Market Open |
5.84 |
| Regular Market Previous Close |
6.34 |
| Regular Market Price |
5.71 |
| Regular Market Time |
1,783,972,800 |
| Regular Market Volume |
6,306 |
| Return On Assets |
-0.23591 |
| Return On Equity |
-1.2228 |
| Revenue Growth |
-0.892 |
| Revenue Per Share |
0.12 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
1,265,844 |
| Shares Percent Shares Out |
0.0011999999 |
| Shares Short |
1,509 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
4,982 |
| Short Name |
Addex Therapeutics Ltd |
| Short Percent Of Float |
0.0014 |
| Short Ratio |
0.3 |
| Source Interval |
15 |
| Symbol |
ADXN |
| Total Cash |
935,153 |
| Total Cash Per Share |
0.94 |
| Total Debt |
102,269 |
| Total Revenue |
109,496 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-8.49 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
7.508915 |
| Two Hundred Day Average Change |
-1.7989149 |
| Two Hundred Day Average Change Percent |
-0.23957056 |
| Type Disp |
Equity |
| Volume |
6,306 |
| Website |
https://www.addextherapeutics.com |
| Zip |
1,202 |